{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12"],"submitter":["Petrocchi S"],"funding":["Innovative Medicines Initiative"],"pubmed_abstract":["<b>Background:</b> The potential value of patient preference studies has been recognized in clinical individual treatment decision-making between clinicians and patients, as well as in upstream drug decision-making. Drug developers, regulators, reimbursement and Health Technology Assessment (HTA) bodies are exploring how the use of patient preference studies could inform drug development, regulatory benefit risk-assessment and reimbursement decisions respectively. Understanding patient preferences may be especially valuable in decisions regarding Non-Small Cell Lung Cancer (NSCLC) treatment options, where a variety of treatment options with different characteristics raise uncertainty about which features are most important to NSCLC patients. As part of the Innovative Medicines Initiative P"],"journal":["Frontiers in pharmacology"],"pagination":["602112"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7970036"],"repository":["biostudies-literature"],"pubmed_title":["What Matters Most to Lung Cancer Patients? A Qualitative Study in Italy and Belgium to Investigate Patient Preferences."],"pmcid":["PMC7970036"],"pubmed_authors":["Smith MY","Louis E","Pravettoni G","Vandevelde M","Arnou R","Oliveri S","Petrocchi S","Durosini I","Janssens R","Galli G","de Marinis F","Nackaerts K","Huys I","Guiddi P","Gianoncelli L"],"additional_accession":[]},"is_claimable":false,"name":"What Matters Most to Lung Cancer Patients? A Qualitative Study in Italy and Belgium to Investigate Patient Preferences.","description":"<b>Background:</b> The potential value of patient preference studies has been recognized in clinical individual treatment decision-making between clinicians and patients, as well as in upstream drug decision-making. Drug developers, regulators, reimbursement and Health Technology Assessment (HTA) bodies are exploring how the use of patient preference studies could inform drug development, regulatory benefit risk-assessment and reimbursement decisions respectively. Understanding patient preferences may be especially valuable in decisions regarding Non-Small Cell Lung Cancer (NSCLC) treatment options, where a variety of treatment options with different characteristics raise uncertainty about which features are most important to NSCLC patients. As part of the Innovative Medicines Initiative P","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2025-04-04T22:00:37.921Z","creation":"2025-04-04T22:00:37.921Z"},"accession":"S-EPMC7970036","cross_references":{"pubmed":["33746750"],"doi":["10.3389/fphar.2021.602112"]}}